# Respiratory Agents: Monoclonal Antibodies-Anti-IL/Anti-IgE

**LENGTH OF AUTHORIZATIONS:** 365 Days

**Clinical Criteria for Asthma**

- Indicated for **moderate to severe asthma** if: o Prescribed by or in consultation with an allergist/immunologist or pulmonologist o Preferred medications will be approved for patients with uncontrolled eosinophilic asthma symptoms and/or exacerbations despite at least 30 days adherence to therapy with:

-   Medium dose preferred ICS/LABA inhaler (patients 6-11 years old) – Nucala only
-   Medium dose preferred ICS/LABA inhaler with tiotropium or high dose preferred

    ICS/LABA inhaler (patients 12 years and older) – Nucala or Fasenra

-   Non-preferred medications will be approved for patients with uncontrolled eosinophilic asthma symptoms and/or exacerbations despite at least 90 days adherence to therapy with a preferred agent

**ADDITIONAL CRITERIA FOR DUPILUMAB (DUPIXENT)**

- Indicated for **moderate to** **severe atopic dermatitis** if: o Patient has minimum body surface area (BSA) involvement of at least 10% o Prescribed by or in consultation with a dermatologist or allergist/immunologist o Patient is 6 years of age or older o Patient has had inadequate response or contraindication to two of the following: topical corticosteroids, topical calcineurin inhibitors [e.g. Elidel], or topical PDE-4 inhibitors [e.g. Eucrisa™] unless atopic dermatitis is severe and involves greater than 25% of BSA.

-   Initial authorization is limited to 112 days with re-authorization of up to 365 days granted following demonstration of improvement in patient condition with therapy (e.g.

    reduced BSA affected).

- Indicated for **chronic rhinosinusitis with nasal polyposis** if: o Patient is 18 years of age or older

-   Patient had an inadequate response, intolerance or contraindication to one oral corticosteroid
-   Patient had a 30-day trial and experienced an inadequate response, intolerance or contraindication to one nasal corticosteroid spray

**ADDITIONAL CRITERIA FOR OMALIZUMAB (XOLAIR)**

- Indicated for **chronic** **urticaria** if: o Patient has tried and failed two 14-day trials with two different antihistamines o Prescribed by or in consultation with a dermatologist or allergist/immunologist o Prescribed in accordance with its FDA approved labeling

- Indicated for **chronic rhinosinusitis with nasal polyposis** if: o Patient is 18 years of age or older

-   Patient had an inadequate response, intolerance or contraindication to one oral corticosteroid
-   Patient had a 30-day trial and experienced an inadequate response, intolerance or contraindication to one nasal corticosteroid spray